Journal of ethnopharmacology
Cure8 research brief
Why This Matters
The study identifies specific small molecules and polysaccharide features in Atractylodes macrocephala that correlated with reduced inflammation in a mouse model of ulcerative colitis, which could guide future preclinical work and quality control of herbal preparations relevant to IBD research.
Who Should Pay Attention
Researchers in natural-product drug discovery, pharmacology, and UC preclinical research; clinicians following complementary/herbal therapy research.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The paper describes lab and animal-model work (not a human trial). Researchers found that the herbal decoctions lessened several disease measures in DSS colitis mice and used spectrum–effect analysis to link specific chemical peaks and polysaccharide traits to those effects.
The identified markers (e.g., atractylenolide II/III and certain monosaccharide compositions) are proposed as quality-control targets and as candidate bioactive components. These results support further preclinical research to validate mechanisms and safety; they do not establish clinical benefit or dosing for people with UC.
If you use herbal products, note that this study examined standardized lab preparations, not commercial supplements, and animal-model findings may not translate to humans.
Keep In Mind
Findings are from DSS-induced colitis in animals and chemical-fingerprinting analyses (preclinical). This does not demonstrate safety or efficacy in humans; results are hypothesis-generating and useful mainly for further laboratory validation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of ethnopharmacology
AuthorsHui Shen, Na Lin, Yi Zheng +4 more
InstitutionCollege of Pharmacy, Anhui University of Chinese Medicine, Hefei 230011, China. Electronic address: 18155602280@163.com.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 11, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of Competing Interest ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Chemical Profiling of Fructus Ailanthi and a Network Pharmacology-Based Mechanistic Study in Ulcerative Colitis.
This study proposes specific plant compounds and molecular pathways that could be relevant to ulcerative colitis, which may guide future lab research and drug-discovery efforts. For people with UC, it points to...
Molecular Mechanisms of Danggui Shaoyao Powder in the Treatment of Ulcerative Colitis: A Network Pharmacology Approach with Experimental Validation.
The study points to specific immune pathways (especially Th17 differentiation) and molecular targets that might explain DSP’s anti-inflammatory effects in ulcerative colitis, which could guide further preclinical and...
Anti-Inflammatory Components of Artemisia scoparia Alleviate Ulcerative Colitis: An Integrated Study Combining UPLC-Q-Exactive Orbitrap MS/MS, Network Pharmacology, Molecular Docking, and In Vivo/In Vitro Validation
The study identifies specific anti-inflammatory compounds in Artemisia scoparia and shows they reduce inflammation in cell and mouse models of ulcerative colitis, suggesting potential new leads for drug or...